Co-Editor-in-Chief


Claudio Feliciani, MD

Associate Professor
Department of Dermatology and Venereology
Dermatology Clinic
University of Parma
Via Gramsci 14-43126 Parma, Italy


Biography

EDUCATIONAL BACKGROUND AND EMPLOYEMENT


• (1988) Graduated in Medicine and surgery at the University G. DAnnunzio Chieti G.dAnnunzio. Final thesis in Dermatology title: Mycosis Fungoides
• (1989-1991) Post doctoral fellowship at the McMaster University, Hamilton, Canada and University of Toronto, Canada
• (1992) Specialist in Dermatology at the University G. DAnnunzio Chieti, with score 70/70, thesis The skin immune system
• (1993) Assistant Professor at the University G. DAnnunzio Chieti
• (1993) Post doctoral fellowship at the University of Ulm, Germany
• (1994) Post doctoral fellowship at the Humboldt University, Berlin, Germany
• (2002) Master in Allergology
• (1996-1997) Sabbatic year at the Universtat Phillipps in Marburg
• (2003) GCP Good clinical practice course
• (2003-10) Associate Professor at University Cattolica del Sacro Cuore, Rome, Italy
• (2010-2013) Director of the school of specialization in Dermatology and Venereology, Rome
• (2014) Associate Professor University of Parma

Research Interest

His research interests include: Autoimmune bullous disorder: chemical mediators of acantholysis, interleukins involved in local inflammation and blister formation.
Fabry disease: development of neovascular elements, proteic mediators involved in proliferative slerotic tissue.

Scientific Activities

HONORS


• (1997-2002) Faculty Co-ordinator, agreements with foreign University (Toronto, Ulm, Berlin)
• (1997-1999) Assistant Professor representative to the Faculty
• (1999-2003) Faculty Coordinator, Continuing medical education
• (1992-Present) teacher in Dermatology in the school of Medicine, Dentistry, Nursery; School of Specialization in Dermatology, Allergology, Geriatric, Internal Medicine

Publications

1. Pagliarello C, Fabrizi G, Ricci R, Tabolli S, Feliciani C, Di Nuzzo S. Side predominance of squamous cell carcinoma: further evidence. J Eur Acad Dermatol Venereol. 2015. doi: 10.1111/jdv.13156
2. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015; 172(4): 867-877. doi: 10.1111/bjd.13717
3. Pagliarello C, Fabrizi G, Fantini C, et al. Calcipotriol/betamethasone dipropionate ointment compared with tacrolimus ointment for the treatment of erosive pustular dermatosis of the scalp: a split-lesion comparison. Eur J Dermatol. 2015; 25(2): 206-208.
4. Di Nuzzo S, Cortelazzi C, Boccaletti V, et al. Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp. Photodermatol Photoimmunol Photomed. 2015; 31(5): 233-238. doi: 10.1111/phpp.12164
5. Zampetti A, Silvestri G, Manco S, et al. Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study. J Am Acad Dermatol. 2015; 72(1): 85-91. doi: 10.1016/j.jaad.2014.09.038
6. Garcovich S, Gnarra M, Murabit A, Arena V, Sani I, Feliciani C. First report of hereditary Christ-Siemens-Touraine syndrome and non-segmental vitiligo association in a young adult: contraindication for vitiligo treatment. J Eur Acad Dermatol Venereol. 2014. doi: 10.1111/jdv.12756
7. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015; 29(3): 405-414. doi: 10.1111/jdv.12772
8. Pagliarello C, Fabrizi G, Cortelazzi C, Boccaletti V, Feliciani C, Di Nuzzo S. Psoriasis and seborrheic dermatitis in infancy and childhood. G Ital Dermatol Venereol. 2014; 149(6): 683-691.
9. Eming R, Hennerici T, Bäcklund J, et al. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J Immunol. 2014; 193(9): 4391-4399. doi: 10.4049/jimmunol.1401081
10. Concolino D, Degennaro E, Parini R, Fabry Delphi working group, Fabry Delphi working group. Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease. Eur J Intern Med. 2014; 25(8): 751-756. doi: 10.1016/j.ejim.2014.07.009.
11. Boccaletti V, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C. An update on juvenile dermatomyositis. G Ital Dermatol Venereol. 2014; 149(5): 519-524.
12. Gnarra M, Saraceni P, Rossi A, et al. Challenging diagnosis of peripillous sheaths. Pediatr Dermatol. 2014; 31(4): e112-e113.
13.Pagliarello C, Fabrizi G, Feliciani C, Di Nuzzo S. Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided. JAMA Dermatol. 2014; 150(7): 765-766. doi: 10.1001/jamadermatol.2014.430
14. Giurdanella F, Fania L, Gnarra M, et al. A possible role for CD8+ T lymphocytes in the cell-mediated pathogenesis of pemphigus vulgaris. Mediators Inflamm. 2013; 2013: 764290. doi: 10.1155/2013/764290
15. Pagliarello C, Pepe CA, Lombardi M, Feliciani C, Fabrizi G, Di Nuzzo S. Early miscarriage during Sweets syndrome: uncommon, but probably not coincidental. Eur J Dermatol. 2013; 23(5): 707-708. doi: 10.1684/ejd.2013.2129
16. Zampetti A, Decinti MD, Gnarra M, Massi G, Feliciani C, Linder D. "Eczema-like" leishmaniasis in an HIV patient. Eur J Dermatol. 2013; 23(4): 542-544. doi: 10.1684/ejd.2013.2079
17. Caldarola G, Fania L, Fossati B, et al. Dermoscopy of melanocytic lesions in patients affected by oculocutaneous albinism: a case series. Dermatology. 2013; 226(4): 358-361. doi: 10.1159/000351315
18. Manna R, Garcovich S, Giovinale M, et al. Systemic complications of esophageal lichen planus. Int J Immunopathol Pharmacol. 2013; 26(2): 575-578.
19. Jones SA, Parini R, Harmatz P, et al. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2013; 109(1): 41-48.
20. Cohn GM, Morin I, Whiteman DA, Hunter Outcome Survey Investigators. Development of a mnemonic screening tool for identifying subjects with Hunter syndrome. Eur J Pediatr. 2013; 172(7): 965-970. doi: 10.1007/s00431-013-1967-x
21. Zampetti A, Giurdanella F, Manco S, et al. Acquired epidermodysplasia verruciformis: a comprehensive review and a proposal for treatment. Dermatol Surg. 2013; 39(7): 974-980. doi: 10.1111/dsu.12135
22. Di Lazzaro V, Pilato F, Profice P, Feliciani C, Renna R. Cerebral hemorrhage in a paucisymptomatic young patient with Fabry disease. J Stroke Cerebrovasc Dis. 2013; 22(7): e254-e255. doi: 10.1016/j.jstrokecerebrovasdis.2012.12.012.
23. Zampetti A, Gnarra M, Borsini W, et al. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement. Cytokine. 2013; 61(3): 933-939. doi: 10.1016/j.cyto.2012.12.011.
24. Zampetti A, Fania L, Antuzzi D, et al. Mutation identification of Fabry disease in families with other lysosomal storage disorders. Clin Genet. 2013; 84(3): 281-285. doi: 10.1111/cge.12071
25. Fania L, Zampetti A, Guerriero G, Feliciani C. Alteration of cholinergic system in keratinocytes cells produces acantholysis: a possible use of cholinergic drugs in pemphigus vulgaris. Antiinflamm Antiallergy Agents Med Chem. 2012; 11(3): 238-242.
26: Tisi MC, Zampetti A, Feliciani C, et al. Small lymphocytic lymphoma in a patient with Fabry disease. Leuk Lymphoma. 2013; 54(1): 184-185. doi: 10.3109/10428194.2012.701294.
27. Minutilli E, Feliciani C. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors. Tumori. 2012; 98(2): 185-190. doi: 10.1700/1088.11928
28. Fania L, Caldarola G, Müller R, et al. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol. 2012; 143(3): 236-245. doi: 10.1016/j.clim.2012.02.003
29. Zampetti A, Orteu CH, Antuzzi D, et al. Angiokeratoma: decision-making aid for the diagnosis of Fabry disease. Br J Dermatol. 2012; 166(4): 712-720. doi: 10.1111/j.1365-2133.2012.10742.x
30. Fania L, Giannico MI, Fasciani R, et al. Ocular mucous membrane pemphigoid after Lyell syndrome: occasional finding or predisposing event? Ophthalmology. 2012; 119(4): 688-693. doi: 10.1016/j.ophtha.2011.09.038.
31. Fasano A, DAgostino M, Caldarola G, Feliciani C, De Simone C. Infliximab monotherapy in neuro-Behçets disease: four year follow-up in a long-standing case resistant to conventional therapies. J Neuroimmunol. 2011; 239(1-2): 105-107. doi: 10.1016/j.jneuroim.2011.08.014.
32. Ferri L, Guido C, la Marca G, et al. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Clin Genet. 2012; 81(3): 224-233. doi: 10.1111/j.1399-0004.2011.01689.x
33. Burton BK, Whiteman DA, HOS Investigators. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011; 103(2): 113-120. doi: 10.1016/j.ymgme.2011.02.018.
34. Caldarola G, Feliciani C. A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris? Expert Rev Clin Immunol. 2011; 7(2): 187-191.
35. Guest JF, Concolino D, Di Vito R, Feliciani C, Parini R, Zampetti A. Modelling the resource implications of managing adults with Fabry disease in Italy. Eur J Clin Invest. 2011; 41(7): 710-718. doi: 10.1111/j.1365-2362.2010.02458.x
36. Caldarola G, Fania L, Cozzani E, Feliciani C, De Simone C. Dyshidrosiform pemphigoid: a well-defined clinical entity? Eur J Dermatol. 2011; 21(1): 112-113. doi: 10.1684/ejd.2010.1172
37. Zampetti A, Gnarra M, Linder D, Digiuseppe MD, Carrino N, Feliciani C. Psoriatic Pseudobalanitis Circinata as a Post-Viral Koebner Phenomenon. Case Rep Dermatol. 2010; 2(3): 183-188. doi: 10.1159/000321012)
38. Mendelsohn NJ, Harmatz P, Bodamer O, et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med. 2010; 12(12): 816-822. doi: 10.1097/GIM.0b013e3181f6e74d
39. Zampetti A, Gnarra M, Linder D, et al. Early-onset basal cell carcinoma in a case of Ivemark syndrome. Eur J Dermatol. 2010; 20(6): 845-846. doi: 10.1684/ejd.2010.1093
40. Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM. 2010; 103(9): 641-659. doi: 10.1093/qjmed/hcq117
41. Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA, HOS investigators. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab. 2010; 101(2-3): 123-129. doi: 10.1016/j.ymgme.2010.06.011
42. Amerio P, Di Rollo D, Carbone A, et al. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases. Eur J Dermatol. 2010; 20(3): 354-358. doi: 10.1684/ejd.2009.0939
43. Zampetti A, Feliciani C, Massi G, Tulli A. Updated review of the pathogenesis and management of Merkel cell carcinoma. J Cutan Med Surg. 2010; 14(2): 51-61.
44. Zampetti A, Mastrofrancesco A, Flori E, et al. Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis. Int J Immunopathol Pharmacol. 2009; 22(4): 1067-1075.
45. Caldarola G, De Simone C, Carbone A, Tulli A, Amerio P, Feliciani C. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. Int J Immunopathol Pharmacol. 2009; 22(4): 961-966.
46. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabrys disease: an analysis of registry data. Lancet. 2009; 374(9706): 1986-1996. doi: 10.1016/S0140-6736(09)61493-8
47. Crucitti A, Feliciani C, Grossi U, et al. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol. 2009; 27(36): e266-e268.
48. Feliciani C, Pennacchia I, Massi G. Adult self-healing papular mucinosis on genital skin. Clin Exp Dermatol. 2009; 34(8): e760-e762. doi: 10.1111/j.1365-2230.2009.03483.x
49. Jones SA, Almássy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009; 32(4): 534-543. doi: 10.1007/s10545-009-1119-7
50. Feliciani C, De Simone C, Amerio P. Dermatological signs during inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009; 13(Suppl 1): 15-21.
51. Feliciani C, Caldarola G, Kneisel A, et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol. 2009; 161(2): 306-312. doi: 10.1111/j.1365-2133.2009.09266.x
52. Zampetti A, Rigante D, Bersani G, Rendeli C, Feliciani C, Stabile A. Longitudinal study of microvascular involvement by nailfold capillaroscopy in children with Henoch-Schönlein purpura. Clin Rheumatol. 2009; 28(9): 1101-1105. doi: 10.1007/s10067-009-1200-5
53. De Simone C, Caldarola G, Dagostino M, Zampetti A, Amerio P, Feliciani C. Exacerbation of pemphigus after influenza vaccination. Clin Exp Dermatol. 2008; 33(6): 718-720. doi: 10.1111/j.1365-2230.2008.02835.x
54. Caldarola G, Kneisel A, Hertl M, Feliciani C. Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations. Eur J Dermatol. 2008; 18(4): 440-443. doi: 10.1684/ejd.2008.0439.
55. Zampetti A, Barone A, Antuzzi D, et al. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years. J Dermatolog Treat. 2008; 19(3): 134-140. doi: 10.1080/09546630701846087
56. Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimers disease. J Alzheimers Dis. 2008; 14(2): 147-159.
57. Cavalieri S, Feliciani C, Massi G, et al. Lymphoepithelioma-like carcinoma of the skin. Int J Immunopathol Pharmacol. 2007; 20(4): 851-854.
58. Veldman C, Feliciani C. Pemphigus: a complex T cell-dependent autoimmune disorder leading to acantholysis. Clin Rev Allergy Immunol. 2008; 34(3): 313-320.
59. Zampetti A, Antuzzi D, Caldarola G, Celleno L, Amerio P, Feliciani C. Linear atrophoderma of Moulin. Eur J Dermatol. 2008; 18(1): 79-80.
60. Feliciani C, Ruocco E, Zampetti A, et al. Tannic acid induces in vitro acantholysis of keratinocytes via IL-1alpha and TNF-alpha. Int J Immunopathol Pharmacol. 2007; 20(2): 289-299.
61. Caproni M, Antiga E, Torchia D, et al. The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus. Clin Immunol. 2007; 124(1): 22-25.
62. Caldarola G, Zampetti A, De Simone C, Massi G, Amerio P, Feliciani C. Circumscribed pityriasis rubra pilaris type IV. Clin Exp Dermatol. 2007; 32(4): 471-472.
63. Zampetti A, Feliciani C, Landi F, Capaldo ML, Rotoli M, Amerio PL. Management and dermoscopy of fast-growing nevi in pregnancy: case report and literature review. J Cutan Med Surg. 2006; 10(5): 249-252.
64. Feliciani C, Motta A, Tortorella R, De Benedetto A, Amerio P, Tulli A. Bullous Wells syndrome. J Eur Acad Dermatol Venereol. 2006; 20(8): 1021-1022.
65. Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol. 2006; 31(5): 746-749. doi: 10.1111/j.1365-2230.2006.02171.x
66. Amerio P, Innocente C, Feliciani C, Angelucci D, Gambi D, Tulli A. Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine. Eur J Dermatol. 2006; 16(3): 281-283.
67. Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimers disease patients. Neuropharmacology. 2006; 50(5): 606-613.
68. Diociaiuti A, Guidi B, Aguilar Sanchez JA, Feliciani C, Capizzi R, Amerio P. Phakomatosis pigmentovascularis type IIIb: a case associated with Sturge-Weber and Klippel-Trenaunay syndromes. J Am Acad Dermatol. 2005; 53(3): 536-539.
69. Zampetti A, Feliciani C, Capizzi R, Valenzano F, Manco S, Amerio PL. Scrofuloderma induced by surgical drainage in a joint tuberculosis. Scand J Infect Dis. 2005; 37(6-7): 540-542. doi: 10.1080/00365540510037830
70.Paradisi A, Capizzi R, Zampetti A, et al. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect. 2005; 51(5): e261-e264. doi: 10.1016/j.jinf.2005.03.012
71. Iarlori C, Gambi D, Gambi F, et al. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimers disease. Exp Gerontol. 2005; 40(7): 605-611. doi: 10.1016/j.exger.2005.04.007
72. Cavalieri S, Rotoli M, Feliciani C, Amerio P. Expression of the high-affinity laminin receptor (67 kDa) in normal human skin and appendages. Int J Immunopathol Pharmacol. 2005; 18(2): 223-231.
73. Feliciani C, Motta A, Castellaneta M, et al. Coexisting pemphigus vulgaris and pemphigus foliaceus in the same patient. Int J Dermatol. 2005; 44(2): 139-141.
74. Amerio P, Motta A, Toto P, et al. Skin toxicity from glyphosate-surfactant formulation. J Toxicol Clin Toxicol. 2004; 42(3): 317-319.
75. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004; 8(2): 122-125.
76. Gambi F, Reale M, Iarlori C, et al. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol. 2004; 24(3): 314-321.
77. Weiss E, Mamelak AJ, La Morgia S, et al. The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J Am Acad Dermatol. 2004; 50(5): 657-675.
78. Reale M, Iarlori C, Gambi F, et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol. 2004; 148(1-2): 162-171. doi: 10.1016/j.jneuroim.2003.11.003
79. Amerio P, Frezzolini A, Feliciani C, et al. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy. 2003; 2(1): 81-94.
80. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol. 2003; 12(4): 466-471. doi: 10.1034/j.1600-0625.2002.120415.x
81. Feliciani C, Toto P, Mohammad Pour S, Coscione G, Amerio P, Amerio P. A Th2-like cytokine response is involved in bullous pemphigoid, the role of IL-4 and IL-5 in the pathogenesis of the disease. Int J Immunopathol Pharmacol. 1999; 12(2): 55-61.
82. Verrotti A, Feliciani C, Morresi S, et al. Carbamazepine-induced hypersensitivity syndrome in a child with epilepsy. Int J Immunopathol Pharmacol. 2000; 13(1): 49-53. doi: 10.1177/039463200001300108
83. Di Carmine M, Toto P, Feliciani C, et al. Spreading of epithelial cells on machined and sandblasted titanium surfaces: an in vitro study. J Periodontol. 2003; 74(3): 289-295. doi: 10.1902/jop.2003.74.3.289
84. Morelli F, De Benedetto A, Toto P, Tulli A, Feliciani C. Alcoholism as a trigger of multiple symmetric lipomatosis? J Eur Acad Dermatol Venereol. 2003; 17(3): 367-369. doi: 10.1046/j.1468-3083.2003.00792_15.x
85.Motta A, Feliciani C, Toto P, De Benedetto A, Morelli F, Tulli A. Lupus vulgaris developing at the site of misdiagnosed scrofuloderma. J Eur Acad Dermatol Venereol. 2003; 17(3): 313-315. doi: 10.1046/j.1468-3083.2003.00783.x
86. Morelli F, Feliciani C, Toto P, De Benedetto A, Tulli A. A minimal form of Proteus syndrome presenting with macrodactyly and hand hyperplasia. Eur J Dermatol. 2003; 13(2): 196-198.
87. Feliciani C, Tulli A. Topical cyclosporin in the treatment of dermatologic diseases. Int J Immunopathol Pharmacol. 2002; 15(2): 89-93.
88. Feliciani C, Verrotti A, Coscione G, et al. Skin reactions due to anti-epileptic drugs: several case-reports with long-term follow-up. Int J Immunopathol Pharmacol. 2003; 16(1): 89-93.
89. Wang B, Feliciani C, Howell BG, et al. Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol. 2002; 168(7): 3303-3308. doi: 10.4049/jimmunol.168.7.3303
90. Reale M, Intorno R, Tenaglia R, et al. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother. 2002; 51(2): 91-98. doi: 10.1007/s00262-001-0254-2
91. Iarlori C, Reale M, De Luca G, et al. Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2002; 123(1-2): 170-179. doi: 10.1016/S0165-5728(01)00487-8
92. Amerio P, Girardelli CR, Proietto G, et al. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol. 2002; 12(2): 165-169.
93. Amerio P, Verdolini R, Proietto G, et al. Role of Th2 cytokines, RANTES and eotaxin in AIDS-associated eosinophilic folliculitis. Acta Derm Venereol. 2001; 81(2): 92-95.
94. Wang B, Feliciani C, Freed I, Cai Q, Sauder DN. Insights into molecular mechanisms of contact hypersensitivity gained from gene knockout studies. J Leukoc Biol. 2001; 70(2): 185-191.
95. Amerio P, Toto P, Feliciani C, et al. Rethinking the role of tumour necrosis factor-alpha in ultraviolet (UV) B-induced immunosuppression: altered immune response in UV-irradiated TNFR1R2 gene-targeted mutant mice. Br J Dermatol. 2001; 144(5): 952-957. doi: 10.1046/j.1365-2133.2001.04181.x
96. Conti P, Barbacane RC, Feliciani C, Reale M. Expression and secretion of RANTES by human peripheral blood CD4+ cells are dependent on the presence of monocytes. Ann Clin Lab Sci. 2001; 31(1): 75-84.
97. Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G. Role of cytomegalovirus replication in alopecia areata pathogenesis. J Cutan Med Surg. 2000; 4(2): 63-65.
98. Caproni M, Giomi B, Cardinali C, et al. Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin Immunol. 2001; 98(2): 264-271. doi: 10.1006/clim.2000.4974
99. Amerio P, Verdolini R, Giangiacomi M, et al. Expression of eotaxin, interleukin 13 and tumour necrosis factor-alpha in dermatitis herpetiformis. Br J Dermatol. 2000; 143(5): 974-978. doi: 10.1046/j.1365-2133.2000.03765.x
100. Feliciani C, Castellaneta M, Amatetti M, et al. Non-lethal Wiskott-Aldrich syndrome: atopic dermatitis-like lesions persist after splenectomy. Int J Dermatol. 2000; 39(5): 398-400. doi: 10.1046/j.1365-4362.2000.00869-2.x
101. Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol. 2000; 107(1): 100-107. doi: 10.1016/S0165-5728(00)00261-7
102. Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol. 2000; 114(1): 71-77. doi: 10.1046/j.1523-1747.2000.00835.x
103. Toto P, Feliciani C, Amerio P, et al. Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. J Immunol. 2000; 164(1): 522-529. doi: 10.4049/jimmunol.164.1.522
104. Feliciani C, Amerio P. Images in clinical medicine. Madelungs disease: inherited from an ancient Mediterranean population? N Engl J Med. 1999; 340(19): 1481. doi: 10.1056/NEJM199905133401906
105. Feliciani C, Toto P, Amerio P. In vitro C3 mRNA expression in Pemphigus vulgaris: complement activation is increased by IL-1alpha and TNF-alpha. J Cutan Med Surg. 1999; 3(3): 140-144.
106. Wang B, Zhuang L, Fujisawa H, et al. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol. 1999; 162(1): 277-283.
107. Conti P, Feliciani C, Barbacane RC, et al. Monocyte chemotactic protein-1 gene expression and translation in formed granulomatous calcified tissue in vivo. Calcif Tissue Int. 1999; 64(1): 57-62.
108. Feliciani C, Di Muzio M, Mohammad Pour S, et al. Suction split as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid. J Eur Acad Dermatol Venereol. 1998; 10(3): 243-247.
109. Caproni M, Feliciani C, Fuligni A, et al. Th2-like cytokine activity in dermatitis herpetiformis. Br J Dermatol. 1998; 138(2): 242-2427.
110. Feliciani C, Pour SM, Toto P, Coscione G, Amerio P. Direct immunofluorescence diagnosis of pemphigus without biopsy. J Cutan Med Surg. 1998; 2(4): 209-211.
111. Conti P, Reale M, Feliciani C, et al. Augmentation of monocyte chemotactic protein-1 and mRNA transcript in chronic inflammatory states induced by potassium permanganate (KMnO4) in vivo. Immunology. 1997; 92(2): 300-306.
112. Feliciani C, Vitullo P, Dorazi G, et al. The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions. Exp Dermatol. 1997; 6(6): 321-327.
113. Feliciani C, Fasciocco D, Franchi A, Amerio P. Epidermolysis bullosa acquisita in a 10-year-old Albanian boy. Br J Dermatol. 1997; 137(2): 307-308.
114. Conti P, Reale M, Barbacane RC, et al. Massive infiltration of basophilic cells in inflamed tissue after injection of RANTES. Immunol Lett. 1997; 58(2): 101-106.
115.Di Muzio A, Di Guglielmo G, Feliciani C, De Luca G, Di Muzio M, Uncini A. Inflammatory myopathy after intravenous streptokinase. Muscle Nerve. 1997; 20(5): 619-621. doi: 10.1002/(SICI)1097-4598(199705)20:5<619::AID-MUS15>3.0.CO;2-R
116. Proietto G, Amatetti M, Amerio P, Angelucci D, Feliciani C, Amerio P. Langerhans cell histiocytosis associated with diabetes insipidus: magnetic resonance imaging. Int J Dermatol. 1996; 35(10): 730-732.
117. Conti P, Bouchet W, Feliciani C, et al. Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells. Mol Cell Biochem. 1996; 155(1): 61-68.
118. Feliciani C, Gupta AK, Sauder DN. Keratinocytes and cytokine/growth factors. Crit Rev Oral Biol Med. 1996; 7(4): 300-318. doi: 10.1177/10454411960070040101
119. Conti P, Boucher W, Letourneau R, et al. Monocyte chemotactic protein-1 provokes mast cell aggregation and [3H]5HT release. Immunology. 1995; 86(3): 434-440.
120. Porreca E, Conti P, Feliciani C, et al. Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells. Atherosclerosis. 1995; 115(2): 181-189. doi: 10.1016/0021-9150(94)05510-P
121. Venner TJ, Sauder DN, Feliciani C, Mckenzie RC. Interleukin-8 and melanoma growth-stimulating activity (GRO) are induced by ultraviolet B radiation in human keratinocyte cell lines. Exp Dermatol. 1995; 4(3): 138-145.
122. Conti P, Feliciani C, Barbacane RC, et al. Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells. Immunology. 1992; 77(2): 245-250.
123. Nozaki S, Feliciani C, Sauder DN. Keratinocyte cytokines. Adv Dermatol. 1992; 7: 83-100.